A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily
Completed · Phase 3 · NCT04983589
Conditions: Presbyopia
At a glance
- Research payments reported, 2025
- $1,070
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 230
About the trial
- Sponsor
- Allergan
- Tested
- Pilocarpine HCl (drug), Vehicle (drug)
- Dates
- Started 2021-09-02; completion 2022-02-11
- Results posted
- Yes
Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). AGN-190584 is an investigational drug being developed for the treatment of presbyopia. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to vehicle. Around 200 participants age 40-55 years with a diagnosis of presbyopia will be enrolled in the study in approximately 20 …
From ClinicalTrials.gov, last updated 2023-03-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1,070 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Joseph R Martel MD Inc DBA Martel Eye Medical Group $1,070
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.